MedTrace Logo

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

NCT01329289 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-02-12

No results posted yet for this study

Summary

The purpose of this study is to determine if adding SOM230 LAR to bortezomib and dexamethasone is better than bortezomib and dexamethasone alone and if it should be investigated further.

Conditions

Interventions

DRUG

SOM230

60 mg intramuscularly (IM) on day 1 of each 28 day cycle

DRUG

Bortezomib

1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.

DRUG

Dexamethasone

20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Pittsburgh

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01329289 on ClinicalTrials.gov